[go: up one dir, main page]

MX2014015631A - Composiciones farmaceuticas y tratamiento de mastitis. - Google Patents

Composiciones farmaceuticas y tratamiento de mastitis.

Info

Publication number
MX2014015631A
MX2014015631A MX2014015631A MX2014015631A MX2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A
Authority
MX
Mexico
Prior art keywords
mastitis
treatment
pharmaceutical compositions
pharmaceutical composition
relates
Prior art date
Application number
MX2014015631A
Other languages
English (en)
Other versions
MX368153B (es
Inventor
Robrecht Froyman
Heinz-Georg Wetzstein
Kristine Fraatz
Wiehl Wolfgang
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014015631(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of MX2014015631A publication Critical patent/MX2014015631A/es
Publication of MX368153B publication Critical patent/MX368153B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica y a procedimientos de tratamiento y/o prevención de mastitis en mamíferos no humanos. Más en particular, la presente invención se refiere al tratamiento de mastitis en vacas. La composición farmacéutica comprende una mezcla de un ácido fosfónico y al menos un agente antimicrobiano.
MX2014015631A 2012-06-29 2013-06-25 Composiciones farmacéuticas y tratamiento de mastitis. MX368153B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666312P 2012-06-29 2012-06-29
PCT/EP2013/063310 WO2014001353A1 (en) 2012-06-29 2013-06-25 Pharmaceutical compositions and treatment of mastitis

Publications (2)

Publication Number Publication Date
MX2014015631A true MX2014015631A (es) 2015-04-09
MX368153B MX368153B (es) 2019-09-20

Family

ID=48672650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015631A MX368153B (es) 2012-06-29 2013-06-25 Composiciones farmacéuticas y tratamiento de mastitis.

Country Status (23)

Country Link
US (1) US10265330B2 (es)
EP (1) EP2866812B1 (es)
JP (1) JP6246804B2 (es)
KR (1) KR20150030707A (es)
CN (2) CN110522914A (es)
AR (1) AR091603A1 (es)
AU (1) AU2013283375B2 (es)
BR (1) BR112014031866A2 (es)
CA (1) CA2877794C (es)
CL (1) CL2014003503A1 (es)
CO (1) CO7240376A2 (es)
CR (1) CR20140594A (es)
DO (1) DOP2014000300A (es)
EC (1) ECSP14033371A (es)
HK (1) HK1206623A1 (es)
IL (1) IL235768A0 (es)
MX (1) MX368153B (es)
NZ (1) NZ702087A (es)
PE (1) PE20150199A1 (es)
PH (1) PH12014502864A1 (es)
RU (1) RU2659430C2 (es)
WO (1) WO2014001353A1 (es)
ZA (1) ZA201500649B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
US8757092B2 (en) 2011-03-22 2014-06-24 Eco-Composites Llc Animal bedding and associated method for preparing the same
CN110522914A (zh) 2012-06-29 2019-12-03 拜尔动物保健有限责任公司 药物组合物和乳腺炎的治疗
RU2662300C2 (ru) * 2013-02-08 2018-07-25 Луода Фарма Пти Лимитед Способы лечения микробных инфекций, в том числе мастита
JP7000021B2 (ja) 2013-03-15 2022-01-19 ジェンザイム・コーポレーション アミン官能性ポリアミド
BR112016005795B1 (pt) 2013-09-16 2022-07-12 Zoetis Services Llc Conjunto de infusão
JP2016088918A (ja) * 2014-11-11 2016-05-23 大山乳業農業協同組合 乳房炎治療・予防用組成物、並びに、乳房炎の治療・予防方法
EP3124016B1 (en) * 2015-07-31 2019-09-04 Warszawski Uniwersytet Medyczny Antipsoriatic emulsion composition comprising cefazolin
WO2018022451A1 (en) * 2016-07-27 2018-02-01 The Trustees Of The University Of Pennsylvania Drug target for treating veterinary infections and methods of using same
KR20220034832A (ko) * 2019-07-11 2022-03-18 가부시키가이샤 세렌 파머 프로토테카증의 신규 치료제
MX2023007631A (es) * 2020-12-24 2023-07-14 Intervet Int Bv Metodos de tratamiento de la mastitis con un compuesto antimicrobiano de ortosomicina.
RU2762088C1 (ru) * 2021-05-05 2021-12-15 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") Способ лечения мастита у коров
CN113368043A (zh) * 2021-06-11 2021-09-10 吉林大学 一种复方阿莫西林乳房注入剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034099A (en) * 1974-03-29 1977-07-05 The Upjohn Company Compositions and method for treating mastitis in milk animals
US4210635A (en) * 1978-02-15 1980-07-01 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS62129217A (ja) * 1985-12-02 1987-06-11 Fujisawa Pharmaceut Co Ltd 医薬用殺菌組成物
KR20010022033A (ko) * 1997-07-29 2001-03-15 후루타 타케시 가축의 유선염 치료방법
JP2007500692A (ja) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 乳房炎及び耳障害を治療するための分散性医薬組成物
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN101744827B (zh) * 2008-12-15 2012-05-30 天津中敖生物科技有限公司 治疗鸡大肠杆菌的药物组合物及其制备方法、应用
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
EP2404601A1 (en) 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
CN101879172B (zh) * 2010-07-13 2012-07-18 杨建彬 头孢噻呋钠复方制剂
EA021846B1 (ru) 2011-05-11 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
CN110522914A (zh) 2012-06-29 2019-12-03 拜尔动物保健有限责任公司 药物组合物和乳腺炎的治疗

Also Published As

Publication number Publication date
KR20150030707A (ko) 2015-03-20
WO2014001353A1 (en) 2014-01-03
JP2015521644A (ja) 2015-07-30
ZA201500649B (en) 2025-10-29
IL235768A0 (en) 2015-01-29
MX368153B (es) 2019-09-20
CO7240376A2 (es) 2015-04-17
CR20140594A (es) 2015-02-06
AR091603A1 (es) 2015-02-18
EP2866812A1 (en) 2015-05-06
CL2014003503A1 (es) 2015-05-04
CA2877794A1 (en) 2014-01-03
US10265330B2 (en) 2019-04-23
PE20150199A1 (es) 2015-01-31
JP6246804B2 (ja) 2017-12-13
NZ702087A (en) 2016-12-23
US20150164926A1 (en) 2015-06-18
PH12014502864A1 (en) 2015-02-23
AU2013283375B2 (en) 2018-04-26
BR112014031866A2 (pt) 2022-02-01
RU2015102562A (ru) 2016-08-20
DOP2014000300A (es) 2015-07-15
RU2659430C2 (ru) 2018-07-02
AU2013283375A1 (en) 2014-12-18
CN104379151A (zh) 2015-02-25
EP2866812B1 (en) 2017-10-04
CN110522914A (zh) 2019-12-03
HK1206623A1 (en) 2016-01-15
ECSP14033371A (es) 2015-09-30
CA2877794C (en) 2020-08-04

Similar Documents

Publication Publication Date Title
ECSP14033371A (es) Composiciones farmacéuticas y tratamiento de mastitis
MX2013003365A (es) Composicion farmaceutica.
PH12016501807A1 (en) Novel compounds
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
NZ708821A (en) Lfa-1 inhibitor formulations
TN2015000371A1 (en) Substituted imidazopyridazines
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
BR112014032759A2 (pt) composições lipídicas de racecadotril
MX2016000163A (es) Pirazolpiridinas sustituidas.
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
UA105260C2 (ru) Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
JOP20190156B1 (ar) أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
BR112015011693A2 (pt) composições fibrinolíticas compreendendo bromelina e nattokinase para a prevenção e tratamento de estados flebotrombóticos
HK1201189A1 (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
EP2594268A4 (en) ANGIOGENIC INHIBITORY COMPOSITION WITH MACROLACTIN A AND A DERIVATIVELY AS ACTIVE SUBSTANCES
WO2014031982A3 (en) Methods and compositions for treating pain
EA201270547A1 (ru) Фармацевтическая композиция
MX2019012608A (es) Composiciones antimicrobianas con agentes efervescentes.
MA39762A (fr) Nouveaux composés
PL402105A1 (pl) Kompozycja i preparat zawierające tioprolinę i kwas rozmarynowy, zastosowanie tej kompozycji oraz sposób ochrony skóry przed procesem starzenia zewnętrzpochodnego
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.

Legal Events

Date Code Title Description
FG Grant or registration